Kupffer Phase Radiomics Signature in Sonazoid Contrast‐Enhanced Ultrasound Predicts Immunohistochemistry Marker Expression in Hepatocellular Carcinoma
Cancer Medicine · 2025
DOI: 10.1002/cam4.71153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Chen Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences an…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Biomarkers, Tumor, Contrast Media. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Few studies have explored the value of radiomics signatures in predicting immunohistochemical (IHC) staining markers. This study aimed to investigate and validate radiomics models based on the Kupffer phase of Sonazoid contrast‐enhanced intraoperative ultrasonography (S‐CEUS) images for predicting IHC marker expression in hepatocellular carcinoma (HCC).
Method
Overall, 113 consecutive patients diagnosed with HCC between November 2019 and May 2023 were retrospectively analyzed. Histopathological assessment included IHC staining for GS, CD10, GPC3, and HSP70. Radiomic features extracted from S‐CEUS images were selected and analyzed. A Naïve Bayes classifier was employed to predict IHC marker expression in HCC, using selected clinical biomarkers and radiomic features.
Results
For GPC3, the radiomics classifier achieved a macro‐average area under the receiver operating characteristic curve (AUC) of 0.700, indicating strong performance. For GS, both radiomics and combined clinical‐radiomics classifiers exhibited strong discrimination (AUCs: 0.870 and 0.882, respectively). The radiomics classifier outperformed clinical biomarkers (total and direct bilirubin) in predicting CD10, with a macro‐average AUC of 0.834. However, its accuracy decreased for higher HSP70 marker expression levels (AUC: 0.694). These findings underscore the consistent effectiveness of radiomics across different IHC markers when compared to traditional clinical approaches.
Conclusions
The Kupffer phase in the S‐CEUS‐based radiomics signature is an excellent biomarker for predicting IHC marker expression in patients with HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Ultrasound, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of General Surgey, Beijing hospital, National Center of Geronotology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of Ultrasound, The first Affliated Hospital of China Medical University, Shenyang, China.
ORCID-Profile: Chen Li
Zitieren
APA
Li, C., Liu, Y., Wu, M., Dai, W., Song, J., & Wang, Y. (2025). Kupffer Phase Radiomics Signature in Sonazoid Contrast‐Enhanced Ultrasound Predicts Immunohistochemistry Marker Expression in Hepatocellular Carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.71153
Vancouver
Li C, Liu Y, Wu M, Dai W, Song J, Wang Y. Kupffer Phase Radiomics Signature in Sonazoid Contrast‐Enhanced Ultrasound Predicts Immunohistochemistry Marker Expression in Hepatocellular Carcinoma. Cancer Medicine. 2025. doi:10.1002/cam4.71153
BibTeX
@article{Li2025,
author = {Li, Chen and Liu, Yuan and Wu, Mingxiao and Dai, Weide and Song, Jinghai and Wang, Yong},
title = {Kupffer Phase Radiomics Signature in Sonazoid Contrast‐Enhanced Ultrasound Predicts Immunohistochemistry Marker Expression in Hepatocellular Carcinoma},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71153}
}
EUVIMED